PROLOR Biotech To Present At Oppenheimer 23rd Annual Healthcare Conference
NES-ZIONA, Israel, Dec. 10, 2012 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE MKT:PBTH) today announced that company management will give a corporate presentation at the Oppenheimer 23rd Annual Healthcare Conference on December 12, 2012 at 9:25 am EST. The conference is being held December 12-13, 2012 at the Waldorf Astoria Hotel in New York City.
A live webcast of the company's presentation will be available at http://www.veracast.com/webcasts/opco/healthcare2012/14104417.cfm. An archived version of the webcast will be available for 90 days beginning about three hours after the live presentation.
For more information about the Oppenheimer 23rd Annual Healthcare Conference, visit http://www.opco.com/Conferences/healthcare12/index.html.
PROLOR Biotech, Inc. is a clinical stage biopharmaceutical company applying unique technologies, including patented CTP technology and its long-acting reversible-pegylation technology, primarily to develop longer-acting proprietary versions of already approved therapeutic proteins that currently generate billions of dollars in annual global sales. The CTP technology is applicable to virtually all proteins. PROLOR is developing a long-acting version of human growth hormone, which successfully completed a Phase II clinical trial. It also is developing long-acting versions of Factor VIIa and Factor IX for hemophilia and a GLP-1/Glucagon dual receptor agonist peptide for diabetes and obesity, all of which are in preclinical development. For more information, visit www.prolor-biotech.com.
SOURCE PROLOR Biotech, Inc.